Immuno-Oncology News Articles

Napabucasin Plus Pembrolizumab Shows Early Promise in mCRC
Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.
CMV Vaccine Falls Short in Phase III Trial
ASP0113, an investigational DNA vaccine developed for cytomegalovirus-seropositive hematopoietic stem cell transplant patients, has failed to meet its primary and secondary endpoints.
Ipilimumab Approved in Europe for Pediatric Melanoma
Ipilimumab has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.
Pembrolizumab Promising After Sorafenib in Advanced HCC
Treatment with the PD-1 inhibitor pembrolizumab elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.
Cetuximab Plus Pembrolizumab Well Tolerated in RAS Wild-Type mCRC
The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer.
Nivolumab/Ipilimumab Combo Data Encouraging in Advanced GISTs
Nivolumab alone and in combination with ipilimumab induced responses in patients with heavily pretreated gastrointestinal stromal tumor.
Published Data Demonstrate Avelumab Activity in Platinum-Refractory Bladder Cancer
The PD-L1 inhibitor avelumab induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.
Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial
Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.
Combinations Continue to Advance RCC Treatment
Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.
Finding the Best Spot for PD-1/PD-L1 Antibodies in Advanced Lung Cancer
Amid rapid-fire developments in non–small cell lung cancer (NSCLC) research, the role of checkpoint immunotherapy continues to mature.
Publication Bottom Border
Border Publication
x